|Synonyms||vitamin B12, vitamin B-12|
|by mouth, IV, IM, intranasal|
|Bioavailability||Readily absorbed in distal half of the ileum|
|Protein binding||Very high to specific transcobalamins plasma proteins
Binding of hydroxocobalamin is slightly higher than cyanocobalamin.
|Biological half-life||Approximately 6 days
(400 days in the liver)
|Chemical and physical data|
|Molar mass||1355.37 g/mol|
|3D model (JSmol)|
|(what is this?)|
Vitamin B12, also called cobalamin, is a water-soluble vitamin that has a key role in the normal functioning of the brain and nervous system via the synthesis of myelin (myelinogenesis), and the formation of red blood cells. It is one of eight B vitamins. It is involved in the metabolism of every cell of the human body, especially affecting DNA synthesis, fatty acid and amino acid metabolism. No fungi, plants, or animals (including humans) are capable of producing vitamin B12. Only bacteria and archaea have the enzymes needed for its synthesis. Some substantial sources of B12 include animal products (shellfish, meat), fortified food products, and dietary supplements. B12 is the largest and most structurally complicated vitamin and can be produced industrially through bacterial fermentation synthesis, typically used to manufacture B12 for fortified foods and supplements. It can also be produced synthetically via vitamin B12 total synthesis.
Vitamin B12 consists of a class of chemically related compounds (vitamers), all of which show pharmacological activity. It contains the biochemically rare element cobalt (chemical symbol Co) positioned in the center of a planar tetra-pyrrole ring called a corrin ring. The vitamer is produced by bacteria as hydroxocobalamin, but conversion between different forms of the vitamin occurs in the body after consumption.
Vitamin B12 was discovered as a result of its relationship to the disease pernicious anemia, an autoimmune disease in which parietal cells of the stomach responsible for secreting intrinsic factor are destroyed; these cells are also responsible for secreting acid in the stomach. Because intrinsic factor is crucial for the normal absorption of B12, its lack in the presence of pernicious anemia causes a vitamin B12 deficiency. Many other subtler kinds of vitamin B12 deficiency and their biochemical effects have since been made clear. Due to impairment of vitamin B12 absorption during aging, people over age 60 are at risk of deficiency.
- 1 Deficiency
- 2 Dietary recommendations
- 3 Medical use
- 4 Sources
- 5 Interactions
- 6 Pharmacology
- 7 Chemistry
- 8 Synthesis and industrial production
- 9 History
- 10 See also
- 11 References
- 12 External links
Vitamin B12 deficiency can potentially cause severe and irreversible damage, especially to the brain and nervous system. At levels only slightly lower than normal, a range of symptoms such as fatigue, lethargy, depression, poor memory, breathlessness, headaches, and pale skin, among others, may be experienced, especially in elderly people (over age 60) who produce less stomach acid as they age, thereby increasing their probability of B12 deficiencies. Vitamin B12 deficiency can also cause symptoms of mania and psychosis.
Vitamin B12 deficiency is most commonly caused by low intakes, but can also result from malabsorption, certain intestinal disorders, low presence of binding proteins, and use of certain medications. Vitamin B12 is rare from plant sources, so vegetarians are more likely to suffer from vitamin B12 deficiency. Infants are at a higher risk of vitamin B12 deficiency if they were born to vegetarian mothers. The elderly who have diets with limited meat or animal products are vulnerable populations as well. Vitamin B12 deficiency may occur in between 40% to 80% of the vegetarian population who are not also consuming a vitamin B12 supplement. In Hong Kong and India, vitamin B12 deficiency has been found in roughly 80% of the vegan population as well.
Vitamin B12 is a co-substrate of various cell reactions involved in methylation synthesis of nucleic acid and neurotransmitters. Synthesis of the trimonoamine neurotransmitters can enhance the effects of a traditional antidepressant. The intracellular concentrations of vitamin B12 can be inferred through the total plasma concentration of homocysteine, which can be converted to methionine through an enzymatic reaction that uses 5-methyltetrahydrofolate as the methyl donor group. Consequently, the plasma concentration of homocysteine falls as the intracellular concentration of vitamin B12 rises. The active metabolite of vitamin B12 is required for the methylation of homocysteine in the production of methionine, which is involved in a number of biochemical processes including the monoamine neurotransmitters metabolism. Thus, a deficiency in vitamin B12 may impact the production and function of those neurotransmitters.
The U.S. Institute of Medicine (IOM) updated Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for vitamin B12 in 1998. The current EAR for vitamin B12 for women and men ages 14 and up is 2.0 μg/day; the RDA is 2.4 μg/day. RDAs are higher than EARs so as to identify amounts that will cover people with higher than average requirements. RDA for pregnancy equals 2.6 μg/day. RDA for lactation equals 2.8 μg/day. For infants up to 12 months the Adequate Intake (AI) is 0.4–0.5 μg/day. (AIs are established when there is insufficient information to determine EARs and RDAs.) For children ages 1–13 years the RDA increases with age from 0.9 to 1.8 μg/day. Because 10 to 30 percent of older people may be unable to effectively absorb vitamin B12 naturally occurring in foods, it is advisable for those older than 50 years to meet their RDA mainly by consuming foods fortified with vitamin B12 or a supplement containing vitamin B12. As for safety, the IOM sets Tolerable Upper Intake Levels (known as ULs) for vitamins and minerals when evidence is sufficient. In the case of vitamin B12 there is no UL, as there is no human data for adverse effects from high doses. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs).
The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL defined the same as in United States. For women and men over age 18 the Adequate Intake (AI) is set at 4.0 μg/day. AI for pregnancy is 4.5 μg/day, for lactation 5.0 μg/day. For children aged 1–17 years the AIs increase with age from 1.5 to 3.5 μg/day. These AIs are higher than the U.S. RDAs. The EFSA also reviewed the safety question and reached the same conclusion as in United States - that there was not sufficient evidence to set a UL for vitamin B12.
For U.S. food and dietary supplement labeling purposes the amount in a serving is expressed as a percent of Daily Value (%DV). For vitamin B12 labeling purposes 100% of the Daily Value was 6.0 μg, but as of May 27, 2016 was revised downward to 2.4 μg. A table of the old and new adult Daily Values is provided at Reference Daily Intake. The original deadline to be in compliance was July 28, 2018, but on September 29, 2017 the FDA released a proposed rule that extended the deadline to January 1, 2020 for large companies and January 1, 2021 for small companies.
Vitamin B12 is used to treat vitamin B12 deficiency, cyanide poisoning, and hereditary deficiency of transcobalamin II. It is given as part of the Schilling test for detecting pernicious anemia.
For cyanide poisoning, a large amount of hydroxocobalamin may be given intravenously and sometimes in combination with sodium thiosulfate. The mechanism of action is straightforward: the hydroxycobalamin hydroxide ligand is displaced by the toxic cyanide ion, and the resulting harmless B12 complex is excreted in urine. In the United States, the Food and Drug Administration approved (in 2006) the use of hydroxocobalamin for acute treatment of cyanide poisoning.
Elevated serum B12 as disease marker
Elevated levels of serum B12 (cobalamin above about 600 pmol/L) in the absence of dietary supplementation or injections may be a diagnostic sign of serious disease. In such cases B12 is thought to be a marker for disease, not the causal agent.
One cause of elevated cobalamin is general liver disease, since hepatic cytolysis releases B12, and the affected liver shows decreased cobalamin clearance. Thus, acute hepatitis, cirrhosis, hepatocellular carcinoma and metastatic liver disease can also be accompanied by an increase in circulating cobalamin. Elevated B12 levels have been suggested as a predictor of ICU mortality risk, but a recent study of this found that "[e]levated B12 levels are not a significant predictor of mortality after ICU admission when liver function is controlled for, and may instead be a proxy for poor liver function."
A second group of non-supplemented patients with high cobalamin levels have them due to enhanced production of the plasma B12 transporters haptocorrin and transcobalamin II. This happens in hematologic disorders like chronic myelogeneous leukemia, promyelocytic leukemia, polycythemia vera and also the hypereosinophilic syndrome. Increased cobalamin levels are one of the diagnostic criteria for the latter two diseases.
A third group of non-supplemented patients with high cobalamin levels may be at immediate (mostly within one year of testing) higher risk for new diagnosis of certain smoking and alcohol-related cancers which are non-hematologic. In a study of 333,000 persons in Denmark, those with elevated B12 had a three to six times higher standard incidence ratio, with respect to those with normal B12 levels, for later development of certain types of cancer.
Thus, one review states: "Altogether it can be concluded that an observed elevation of cobalamin in blood merits a full diagnostic work up to assess the presence of disease."
Animals store vitamin B12 in liver and muscle and some pass the vitamin into their eggs and milk; meat, liver, eggs and milk are therefore sources of the vitamin for other animals, including people. For humans, the bioavailability from eggs is less than 9%, compared to 40% to 60% from fish, fowl and meat. Insects are a source of B12 for animals (including other insects and humans).
Animal sources with a significant content of vitamin B12 (range among top 20 sources of 50 to 99 µg per 100 grams) include clams, organ meats (especially liver) from lamb, veal, beef, and turkey, fish eggs, mackerel, and crab meat.
B12 is produced in nature only by some prokaryotes (certain bacteria and archaea); it is not made by any multicellular or single-celled eukaryotes. It is synthesized by some gut bacteria in humans and other animals, but humans cannot absorb the B12 made in their guts, as it is made in the colon which is too far from the small intestine, where absorption of B12 occurs. Ruminants, such as cows and sheep, absorb B12 produced by bacteria in their guts. For gut bacteria of ruminants to produce B12 the animal must consume sufficient amounts of cobalt.
Grazing animals pick up B12 and bacteria that produce it from the soil at the roots of the plants they eat.
Feces are a rich source of vitamin B12 and many species, including, dogs, and cats eat feces. Species within the Lagomorpha (rabbits, hares, and pikas) produce two types of fecal pellets: hard ones, and soft ones called cecotropes. Animals in these species re-ingest their own cecotropes, which consist of chewed plant material that was metabolized by bacteria in the cecum, a chamber between the small and large intestines. Cecotropes contain digestible carbohydrates and B vitamins synthesized by the resident bacteria.
Fortified foods and supplements
The UK Vegan Society, the Vegetarian Resource Group, and the Physicians Committee for Responsible Medicine, among others, recommend that every vegan who is not consuming adequate B12 from fortified foods take supplements.
Vitamin B12 is an ingredient in multi-vitamin pills and in some countries used to enrich grain-based foods such as bread and pasta. In the U.S. non-prescription products can be purchased providing up to 5,000 µg per serving, and it is a common ingredient in energy drinks and energy shots, usually at many times the recommended dietary allowance of B12. The vitamin can also be a prescription product via injection or other means.
The sublingual route, in which B12 is presumably or supposedly taken in more directly under the tongue, has not proven to be necessary or helpful, even though a number of lozenges, pills, and even a lollipop designed for sublingual absorption are being marketed. A 2003 study found no significant difference in absorption for serum levels from oral versus sublingual delivery of 0.5 mg of cobalamin. Sublingual methods of replacement are effective only because of the typically high doses (0.5 mg), which are swallowed, not because of placement of the tablet. As noted below, such very high doses of oral B12 may be effective as treatments, even if gastrointestinal tract absorption is impaired by gastric atrophy (pernicious anemia).
Injection and patches are sometimes used if digestive absorption is impaired, but there is evidence that this course of action may not be necessary with modern high-potency oral supplements (such as 0.5–1 mg or more). Even pernicious anemia can be treated entirely by the oral route. These supplements carry such large doses of the vitamin that 1% to 5% of high oral doses of free crystalline B12 is absorbed along the entire intestine by passive diffusion.
If the person has inborn errors in the methyltransfer pathway (cobalamin C disease, combined methylmalonic aciduria and homocystinuria), treatment with intravenous, intramuscular hydroxocobalamin or transdermal B12 is needed.
Non-cyanide forms as supplements
Sublingual methylcobalamin has become available in 5 mg tablets. The metabolic fate and biological distribution of methylcobalamin are expected to be similar to that of other sources of vitamin B12 in the diet. No cyanide is released with methylcobalamin, and the amount of cyanide (20 µg) in a 1,000 µg cyanocobalamin tablet is less than daily consumption from food. Safety of all forms of the vitamin is well established.
Many other sources have found to contain cobalamin but are insufficiently tested to establish whether B12 is bioavailable in humans or whether it is an inactive B12 analogue. Besides certain fermented foods, there are few known plant, fungus or algae sources of biologically active B12, with none tested in human trials.[needs update] Examples include tempeh (B12 content up to 8 µg per 100 grams) and certain species of mushrooms (up to 3 µg per 100 grams). Many algae are rich in vitamin B12, with some species, such as Porphyra yezoensis, containing as much cobalamin as liver.
Pseudovitamin-B12 refers to B12-like analogues that are biologically inactive in humans and yet found to be present alongside B12 in humans, many food sources (including animals), and possibly supplements and fortified foods. Most cyanobacteria, including Spirulina, and some algae, such as dried Asakusa-nori (Porphyra tenera), have been found to contain mostly pseudovitamin-B12 instead of biologically active B12.
- H2-receptor antagonists: include cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), and ranitidine (Zantac). Reduced secretion of gastric acid and pepsin produced by H2 blockers can reduce absorption of protein-bound (dietary) vitamin B12, but not of supplemental vitamin B12. Gastric acid is needed to release vitamin B12 from protein for absorption. Clinically significant vitamin B12 deficiency and megaloblastic anemia are unlikely, unless H2 blocker therapy is prolonged (2 years or more), or the person's diet is poor. It is also more likely if the person is rendered achlorhydric(with complete absence of gastric acid secretion), which occurs more frequently with proton pump inhibitors than H2 blockers. Vitamin B12 levels should be monitored in people taking high doses of H2 blockers for prolonged periods.
- Metformin (Glucophage): Metformin may reduce serum folic acid and vitamin B12 levels. Long-term use of metformin substantially increases the risk of B12 deficiency and (in those patients who become deficient) hyperhomocysteinemia, which is "an independent risk factor for cardiovascular disease, especially among individuals with type 2 diabetes". There are also rare reports of megaloblastic anemia in people who have taken metformin for five years or more. Reduced serum levels of vitamin B12 occur in up to 30% of people taking metformin chronically. Clinically significant deficiency is not likely to develop if dietary intake of vitamin B12 is adequate. Deficiency can be corrected with vitamin B12 supplements even if metformin is continued. The metformin-induced malabsorption of vitamin B12 is reversible by oral calcium supplementation. The general clinical significance of metformin upon B12 levels is as yet unknown.
- Proton pump inhibitors (PPIs): The PPIs include omeprazole (Prilosec, Losec), lansoprazole (Prevacid), rabeprazole (Aciphex), pantoprazole (Protonix, Pantoloc), and esomeprazole (Nexium). The reduced secretion of gastric acid and pepsin produced by PPIs can reduce absorption of protein-bound (dietary) vitamin B12, but not supplemental vitamin B12. Gastric acid is needed to release vitamin B12 from protein for absorption. Reduced vitamin B12 levels may be more common with PPIs than with H2 antagonists, because they are more likely to produce achlorhydria (complete absence of gastric acid secretion). Clinically significant vitamin B12 deficiency is unlikely, unless PPI therapy is prolonged (2 years or more) or dietary vitamin intake is low. Vitamin B12 levels should be monitored in people taking high doses of PPIs for prolonged periods.
Mechanism of action
- Rearrangements in which a hydrogen atom is directly transferred between two adjacent atoms with concomitant exchange of the second substituent, X, which may be a carbon atom with substituents, an oxygen atom of an alcohol, or an amine. These use the adoB12 (adenosylcobalamin) form of the vitamin.
- Methyl (–CH3) group transfers between two molecules. These use MeB12 (methylcobalamin) form of the vitamin.
- Reactions in which a halogen atom is removed from an organic molecule. Enzymes in this class have not been identified in humans.
In humans, two major coenzyme B12-dependent enzyme families corresponding to the first two reaction types, are known. These are typified by the following two enzymes:
- MUT is an isomerase which uses the AdoB12 form and reaction type 1 to catalyze a carbon skeleton rearrangement (the X group is -COSCoA). MUT's reaction converts MMl-CoA to Su-CoA, an important step in the extraction of energy from proteins and fats (for more see MUT's reaction mechanism). This functionality is lost in vitamin B12 deficiency, and can be measured clinically as an increased methylmalonic acid (MMA) level. Unfortunately, an elevated MMA, though sensitive to B12 deficiency, is probably overly sensitive, and not all who have it actually have B12 deficiency. For example, MMA is elevated in 90–98% of patients with B12 deficiency; 20–25% of patients over the age of 70 have elevated levels of MMA, yet 25–33% of them do not have B12 deficiency. For this reason, assessment of MMA levels is not routinely recommended in the elderly. There is no "gold standard" test for B12 deficiency because as a B12 deficiency occurs, serum values may be maintained while tissue B12 stores become depleted. Therefore, serum B12 values above the cut-off point of deficiency do not necessarily indicate adequate B12 status. The MUT function is necessary for proper myelin synthesis (see mechanism below) and is not affected by folate supplementation.
- MTR, also known as methionine synthase, is a methyltransferase enzyme, which uses the MeB12 and reaction type 2 to transfer a methyl group from 5-methyltetrahydrofolate to homocysteine, thereby generating tetrahydrofolate (THF) and methionine (for more see MTR's reaction mechanism). This functionality is lost in vitamin B12 deficiency, resulting in an increased homocysteine level and the trapping of folate as 5-methyl-tetrahydrofolate, from which THF (the active form of folate) cannot be recovered. THF plays an important role in DNA synthesis so reduced availability of THF results in ineffective production of cells with rapid turnover, in particular red blood cells, and also intestinal wall cells which are responsible for absorption. THF may be regenerated via MTR or may be obtained from fresh folate in the diet. Thus all of the DNA synthetic effects of B12 deficiency, including the megaloblastic anemia of pernicious anemia, resolve if sufficient dietary folate is present. Thus the best-known "function" of B12 (that which is involved with DNA synthesis, cell-division, and anemia) is actually a facultative function which is mediated by B12-conservation of an active form of folate which is needed for efficient DNA production. Other cobalamin-requiring methyltransferase enzymes are also known in bacteria, such as Me-H4-MPT, coenzyme M methyltransferase.
If folate is present in quantity, then of the two absolutely vitamin B12-dependent enzyme-family reactions in humans, the MUT-family reactions show the most direct and characteristic secondary effects, focusing on the nervous system (see below). This is because the MTR (methyltransferase-type) reactions are involved in regenerating folate, and thus are less evident when folate is in good supply.
Since the late 1990s, folic acid has begun to be added to fortify flour in many countries, so folate deficiency is now more rare. At the same time, since DNA synthetic-sensitive tests for anemia and erythrocyte size are routinely done in even simple medical test clinics (so that these folate-mediated biochemical effects are more often directly detected), the MTR-dependent effects of B12 deficiency are becoming apparent not as anemia due to DNA-synthetic problems (as they were classically), but now mainly as a simple and less obvious elevation of homocysteine in the blood and urine (homocysteinuria). This condition may result in long term damage to arteries and in clotting (stroke and heart attack), but this effect is difficult to separate from other common processes associated with atherosclerosis and aging.
The specific myelin damage resulting from B12 deficiency, even in the presence of adequate folate and methionine, is more specifically and clearly a vitamin deficiency problem. It has been connected to B12 most directly by reactions related to MUT, which is absolutely required to convert methylmalonyl coenzyme A into succinyl coenzyme A. Failure of this second reaction to occur results in elevated levels of MMA, a myelin destabilizer. Excessive MMA will prevent normal fatty acid synthesis, or it will be incorporated into fatty acids itself rather than normal malonic acid. If this abnormal fatty acid subsequently is incorporated into myelin, the resulting myelin will be too fragile, and demyelination will occur. Although the precise mechanism or mechanisms are not known with certainty, the result is subacute combined degeneration of the central nervous system and spinal cord. Whatever the cause, it is known that B12 deficiency causes neuropathies, even if folic acid is present in good supply, and therefore anemia is not present.
Vitamin B12-dependent MTR reactions may also have neurological effects, through an indirect mechanism. Adequate methionine (which, like folate, must otherwise be obtained in the diet, if it is not regenerated from homocysteine by a B12 dependent reaction) is needed to make S-adenosyl methionine (SAMe), which is in turn necessary for methylation of myelin sheath phospholipids. Although production of SAMe is not B12 dependent, help in recycling for provision of one adequate substrate for it (the essential amino acid methionine) is assisted by B12. In addition, SAMe is involved in the manufacture of certain neurotransmitters, catecholamines and in brain metabolism. These neurotransmitters are important for maintaining mood, possibly explaining why depression is associated with B12 deficiency. Methylation of the myelin sheath phospholipids may also depend on adequate folate, which in turn is dependent on MTR recycling, unless ingested in relatively high amounts.
Absorption and distribution
Methyl-B12 is absorbed by two processes. The first is an intestinal mechanism using intrinsic factor through which 1–2 micrograms can be absorbed every few hours. The second is a diffusion process by which approximately 1% of the remainder is absorbed. The human physiology of vitamin B12 is complex, and therefore is prone to mishaps leading to vitamin B12 deficiency. Protein-bound vitamin B12 must be released from the proteins by the action of digestive proteases in both the stomach and small intestine. Gastric acid releases the vitamin from food particles; therefore antacid and acid-blocking medications (especially proton-pump inhibitors) may inhibit absorption of B12.
B12 taken in a low-solubility, non-chewable supplement pill form may bypass the mouth and stomach and not mix with gastric acids, but acids are not necessary for the absorption of free B12 not bound to protein; acid is necessary only to recover naturally-occurring vitamin B12 from foods.
R-protein (also known as haptocorrin and cobalophilin) is a B12 binding protein that is produced in the salivary glands. It must wait to bind food-B12 until B12 has been freed from proteins in food by pepsin in the stomach. B12 then binds to the R-protein to avoid degradation of it in the acidic environment of the stomach.
This pattern of B12 transfer to a special binding protein secreted in a previous digestive step, is repeated once more before absorption. The next binding protein for B12 is intrinsic factor (IF), a protein synthesized by gastric parietal cells that is secreted in response to histamine, gastrin and pentagastrin, as well as the presence of food. In the duodenum, proteases digest R-proteins and release their bound B12, which then binds to IF, to form a complex (IF/B12). B12 must be attached to IF for it to be efficiently absorbed, as receptors on the enterocytes in the terminal ileum of the small bowel only recognize the B12-IF complex; in addition, intrinsic factor protects the vitamin from catabolism by intestinal bacteria.
Absorption of food vitamin B12 thus requires an intact and functioning stomach, exocrine pancreas, intrinsic factor, and small bowel. Problems with any one of these organs makes a vitamin B12 deficiency possible. Individuals who lack intrinsic factor have a decreased ability to absorb B12. In pernicious anemia, there is a lack of IF due to autoimmune atrophic gastritis, in which antibodies form against parietal cells. Antibodies may alternately form against and bind to IF, inhibiting it from carrying out its B12 protective function. Due to the complexity of B12 absorption, geriatric patients, many of whom are hypoacidic due to reduced parietal cell function, have an increased risk of B12 deficiency. This results in 80–100% excretion of oral doses in the feces versus 30–60% excretion in feces as seen in individuals with adequate IF.
Once the IF/B12 complex is recognized by specialized ileal receptors, it is transported into the portal circulation. The vitamin is then transferred to transcobalamin II (TC-II/B12), which serves as the plasma transporter. Hereditary defects in production of the transcobalamins and their receptors may produce functional deficiencies in B12 and infantile megaloblastic anemia, and abnormal B12 related biochemistry, even in some cases with normal blood B12 levels. For the vitamin to serve inside cells, the TC-II/B12 complex must bind to a cell receptor, and be endocytosed. The transcobalamin-II is degraded within a lysosome, and free B12 is finally released into the cytoplasm, where it may be transformed into the proper coenzyme, by certain cellular enzymes (see above).
Investigations into the intestinal absorption of B12 point out that the upper limit of absorption per single oral dose, under normal conditions, is about 1.5 µg: "Studies in normal persons indicated that about 1.5 µg is assimilated when a single dose varying from 5 to 50 µg is administered by mouth. In a similar study Swendseid et al. stated that the average maximum absorption was 1.6 µg [...]" The bulk diffusion process of B12 absorption noted in the first paragraph above, may overwhelm the complex R-factor and IGF-factor dependent absorption, when oral doses of B12 are very large (a thousand or more µg per dose) as commonly happens in dedicated-pill oral B12 supplementation. It is this last fact which allows pernicious anemia and certain other defects in B12 absorption to be treated with oral megadoses of B12, even without any correction of the underlying absorption defects. See the section on supplements above.
The total amount of vitamin B12 stored in body is about 2–5 mg in adults. Around 50% of this is stored in the liver. Approximately 0.1% of this is lost per day by secretions into the gut, as not all these secretions are reabsorbed. Bile is the main form of B12 excretion; most of the B12 secreted in the bile is recycled via enterohepatic circulation. Excess B12 beyond the blood's binding capacity is typically excreted in urine. Owing to the extremely efficient enterohepatic circulation of B12, the liver can store 3 to 5 years’ worth of vitamin B12; therefore, nutritional deficiency of this vitamin is rare. How fast B12 levels change depends on the balance between how much B12 is obtained from the diet, how much is secreted and how much is absorbed. B12 deficiency may arise in a year if initial stores are low and genetic factors unfavourable, or may not appear for decades. In infants, B12 deficiency can appear much more quickly.
B12 is the most chemically complex of all the vitamins. The structure of B12 is based on a corrin ring, which is similar to the porphyrin ring found in heme, chlorophyll, and cytochrome. The central metal ion is cobalt. Four of the six coordination sites are provided by the corrin ring, and a fifth by a dimethylbenzimidazole group. The sixth coordination site, the center of reactivity, is variable, being a cyano group (–CN), a hydroxyl group (–OH), a methyl group (–CH3) or a 5′-deoxyadenosyl group (here the C5′ atom of the deoxyribose forms the covalent bond with cobalt), respectively, to yield the four B12 forms mentioned below. Historically, the covalent C-Co bond is one of the first examples of carbon-metal bonds to be discovered in biology. The hydrogenases and, by necessity, enzymes associated with cobalt utilization, involve metal-carbon bonds.
Vitamin B12 is a generic descriptor name referring to a collection of cobalt and corrin ring molecules which are defined by their particular vitamin function in the body. All of the substrate cobalt-corrin molecules from which B12 is made must be synthesized by bacteria. After this synthesis is complete, the human body has the ability (except in rare cases) to convert any form of B12 to an active form, by means of enzymatically removing certain prosthetic chemical groups from the cobalt atom and replacing them with others.
The four forms (vitamers) of B12 are all deeply red colored crystals and water solutions, due to the color of the cobalt-corrin complex.
- Cyanocobalamin is one such form, i.e. "vitamer", of B12 because it can be metabolized in the body to an active coenzyme form. The cyanocobalamin form of B12 does not occur in nature normally, but is a byproduct of the fact that other forms of B12 are avid binders of cyanide (–CN) which they pick up in the process of activated charcoal purification of the vitamin after it is made by bacteria in the commercial process. Since the cyanocobalamin form of B12 is easy to crystallize and is not sensitive to air-oxidation, it is typically used as a form of B12 for food additives and in many common multivitamins. Pure cyanocobalamin possesses the deep pink color associated with most octahedral cobalt(II) complexes and the crystals are well formed and easily grown up to millimeter size.
- Hydroxocobalamin is another form of B12 commonly encountered in pharmacology, but which is not normally present in the human body. Hydroxocobalamin is sometimes denoted B12a. This form of B12 is the form produced by bacteria, and is what is converted to cyanocobalmin in the commercial charcoal filtration step of production. Hydroxocobalamin has an avid affinity for cyanide ions and has been used as an antidote to cyanide poisoning. It is supplied typically in water solution for injection. Hydroxocobalamin is thought to be converted to the active enzymic forms of B12 more easily than cyanocobalamin, and since it is little more expensive than cyanocobalamin, and has longer retention times in the body, has been used for vitamin replacement in situations where added reassurance of activity is desired. Intramuscular administration of hydroxocobalamin is also the preferred treatment for pediatric patients with intrinsic cobalamin metabolic diseases, for vitamin B12 deficient patients with tobacco amblyopia (which is thought to perhaps have a component of cyanide poisoning from cyanide in cigarette smoke); and for treatment of patients with pernicious anemia who have optic neuropathy.
- Adenosylcobalamin (adoB12) and methylcobalamin (MeB12) are the two enzymatically active cofactor forms of B12 that naturally occur in the body. Most of the body's reserves are stored as adoB12 in the liver. These are converted to the other methylcobalamin form as needed.
Synthesis and industrial production
Neither plants nor animals are independently capable of constructing vitamin B12. Only bacteria and archaea have the enzymes required for its biosynthesis. Like all tetrapyrroles, it is derived from uroporphyrinogen III. This porphyrinogen is methylated at two pyrrole rings to give dihydrosirohydrochlorin, which is oxidized to sirohydrochlorin, which undergoes further reactions, notably a ring contraction, to give the corrin ring.
The complete laboratory synthesis of B12 was achieved by Robert Burns Woodward and Albert Eschenmoser in 1972, and remains one of the classic feats of organic synthesis, requiring the effort of 91 postdoctoral fellows (mostly at Harvard) and 12 PhD students (at ETH) from 19 nations.
Species from the following genera are known to synthesize B12: Acetobacterium, Aerobacter, Agrobacterium, Alcaligenes, Azotobacter, Bacillus, Clostridium, Corynebacterium, Flavobacterium, Lactobacillus, Micromonospora, Mycobacterium, Nocardia, Propionibacterium, Protaminobacter, Proteus, Pseudomonas, Rhizobium, Salmonella, Serratia, Streptomyces, Streptococcus and Xanthomonas.
Industrial production of B12 is achieved through fermentation of selected microorganisms. Streptomyces griseus, a bacterium once thought to be a yeast, was the commercial source of vitamin B12 for many years. The species Pseudomonas denitrificans and Propionibacterium freudenreichii subsp. shermanii are more commonly used today. These are frequently grown under special conditions to enhance yield, and at least one company, Rhône-Poulenc of France, which has merged into Sanofi-Aventis, used genetically engineered versions of one or both of these species. Since a number of species of Propionibacterium produce no exotoxins or endotoxins and are generally recognized as safe (have been granted GRAS status) by the Food and Drug Administration of the United States, they are presently the FDA-preferred bacterial fermentation organisms for vitamin B12 production.
The total world production of vitamin B12, by four companies (the French Sanofi-Aventis and three Chinese companies) is said to have been 35 tonnes in 2008.
B12 deficiency is the cause of pernicious anemia, an anemic disease that was usually fatal and had unknown etiology when it was first described in medicine. The cure, and B12, were discovered by accident. George Whipple had been doing experiments in which he induced anemia in dogs by bleeding them, and then fed them various foods to observe which diets allowed them fastest recovery from the anemia produced. In the process, he discovered that ingesting large amounts of liver seemed to most rapidly cure the anemia of blood loss. Thus, he hypothesized that liver ingestion might treat pernicious anemia. He tried this and reported some signs of success in 1920.
After a series of clinical studies, George Richards Minot and William Murphy set out to partly isolate the substance in liver which cured anemia in dogs, and found that it was iron. They also found that an entirely different liver substance cured pernicious anemia in humans, that had no effect on dogs under the conditions used. The specific factor treatment for pernicious anemia, found in liver juice, had been found by this coincidence. Minot and Murphy reported these experiments in 1926. This was the first real progress with this disease. Despite this discovery, for several years patients were still required to eat large amounts of raw liver or to drink considerable amounts of liver juice.
In 1928, the chemist Edwin Cohn prepared a liver extract that was 50 to 100 times more potent than the natural liver products. The extract was the first workable treatment for the disease. For their initial work in pointing the way to a working treatment, Whipple, Minot, and Murphy shared the 1934 Nobel Prize in Physiology or Medicine.
These events led to discovery of the soluble vitamin, called vitamin B12, from bacterial broths. In 1947, while working for the Poultry Science Department at the University of Maryland, Mary Shaw Shorb (in a collaborative project with Karl Folkers from Merck.) was provided with a US$400 grant to develop the so-called "LLD assay" for B12. LLD stood for Lactobacillus lactis Dorner, a strain of bacterium which required "LLD factor" for growth, which was eventually identified as B12. Shorb and colleagues used the LLD assay to rapidly extract the anti-pernicious anemia factor from liver extracts, and pure B12 was isolated in this way by 1948, with the contributions of chemists Shorb, Karl A. Folkers of the United States and Alexander R. Todd of Great Britain. For this discovery, in 1949 Mary Shorb and Karl Folkers received the Mead Johnson Award from the American Society of Nutritional Sciences.
The chemical structure of the molecule was determined by Dorothy Crowfoot Hodgkin and her team in 1956, based on crystallographic data. Eventually, methods of producing the vitamin in large quantities from bacteria cultures were developed in the 1950s, and these led to the modern form of treatment for the disease.
- Miller, Ariel; Korem, Maya; Almog, Ronit; Galboiz, Yanina (June 15, 2005). "Vitamin B12, demyelination, remyelination and repair in multiple sclerosis". Journal of the Neurological Sciences. 233 (1–2): 93–97. doi:10.1016/j.jns.2005.03.009. PMID 15896807 – via PubMed.
- "Vitamin B12". April 22, 2014.
- Yamada, Kazuhiro (2013). "Chapter 9. Cobalt: Its Role in Health and Disease". In Sigel, Astrid; Sigel, Helmut; Sigel, Roland K. O. Interrelations between Essential Metal Ions and Human Diseases. Metal Ions in Life Sciences. 13. Springer. pp. 295–320. doi:10.1007/978-94-007-7500-8_9.
- "Vitamin B12". Micronutrient Information Center, Linus Pauling Institute, Oregon State University. 2014. Retrieved February 16, 2017.
- "Foods highest in Vitamin B12 (based on levels per 100-gram serving)". Nutrition Data. Condé Nast, USDA National Nutrient Database, release SR-21. 2014. Retrieved February 16, 2017.
- Scott, J. M.; Molloy, A. M. (November 2012). "The Discovery of Vitamin B12". Annals of Nutrition and Metabolism. 61 (3): 239–245. doi:10.1159/000343114.
- "Dietary Supplement Fact Sheet: Vitamin B12". Office of Dietary Supplements, National Institutes of Health. Retrieved September 28, 2011.
- Van der Put, Nathalie M. J.; Van Straaten, Henny W. M.; Trijbels, Frans J. M.; Blom, Henk J. (April 1, 2001). "Folate, Homocysteine and Neural Tube Defects: An Overview". Experimental Biology and Medicine. 226 (4): 243–270. ISSN 1535-3702. PMID 11368417.
- "Vitamin B12 or folate deficiency anaemia - Symptoms". National Health Service, England. May 16, 2016. Retrieved February 16, 2017.
- Sethi, N. K.; Robilotti, E.; Sadan, Y. (2005). "Neurological Manifestations Of Vitamin B12 Deficiency". Internet Journal of Nutrition and Wellness. 2 (1). doi:10.5580/5a9.
- Masalha, R.; Chudakov, B.; Muhamad, M.; Rudoy, I.; Volkov, I.; Wirguin, I. (2001). "Cobalamin-responsive psychosis as the sole manifestation of vitamin B12 deficiency". Israeli Medical Association Journal. 3 (9): 701–703. PMID 11574992.
- Pawlak, Roman; Parrott, Scott James; Raj, Sudha; Cullum-Dugan, Diana; Lucus, Debbie (February 1, 2013). "How prevalent is vitamin B12 deficiency among vegetarians?". Nutrition Reviews. 71 (2): 110–117. doi:10.1111/nure.12001. ISSN 1753-4887. PMID 23356638.
- Woo, Kam S.; Kwok, Timothy C. Y.; Celermajer, David S. (August 19, 2014). "Vegan Diet, Subnormal Vitamin B12 Status and Cardiovascular Health". Nutrients. 6 (8): 3259–3273. doi:10.3390/nu6083259. ISSN 2072-6643. PMC . PMID 25195560.
- Biemans, E.; Hart, H. E.; Rutten, G. E.; Renteria, V. G. C.; Kooijman-Buiting, A. M.; Beulens, J. W. (2014). "Cobalamin status has a relationship with depression, cognition and neuropathy in patients with Type 2 diabetes mellitus using metformin". Acta Diabetologica: 1–11.
- Bottiglieri, T.; Laundy, M.; Crellin, R.; Toone, B. K.; Carney, M. W.; Reynolds, E. H. (2000). "Homocysteine, folate, methylation, and monoamine metabolism in depression". Journal of Neurology, Neurosurgery & Psychiatry. 69 (2): 228–232. doi:10.1136/jnnp.69.2.228.
- Institute of Medicine (1998). "Vitamin B12". Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: The National Academies Press. pp. 340–342. ISBN 0-309-06554-2. Retrieved February 7, 2012.
- "Overview on Dietary Reference Values for the EU population as derived by the EFSA Panel on Dietetic Products, Nutrition and Allergies" (PDF). 2017.
- "Tolerable Upper Intake Levels For Vitamins And Minerals" (PDF). European Food Safety Authority. 2006.
- "Food Labeling: Revision of the Nutrition and Supplement Facts Labels" (PDF). Federal Register. May 27, 2016. p. 33982.
- "Changes to the Nutrition Facts Panel - Compliance Date"
- "Vitamin B12". The American Society of Health-System Pharmacists. Retrieved April 3, 2011.
- Hall, A. H.; Rumack, B. H. (1987). "Hydroxycobalamin/sodium thiosulfate as a cyanide antidote". Journal of Emergency Medicine. 5 (2): 115–121. doi:10.1016/0736-4679(87)90074-6. PMID 3295013.
- Dart, R. C. (2006). "Hydroxocobalamin for acute cyanide poisoning: new data from preclinical and clinical studies; new results from the prehospital emergency setting". Clinical Toxicology. 44 (Suppl. 1): 1–3. doi:10.1080/15563650600811607. PMID 16990188.
- Callaghan, F. M.; Leishear, K.; Abhyankar, S.; Demner-Fushman, D.; McDonald, C. J. (2014). "High vitamin B12 levels are not associated with increased mortality risk for ICU patients after adjusting for liver function: A cohort study". E-SPEN Journal. 9 (2): e76–e83. doi:10.1016/j.clnme.2014.01.003. PMC . PMID 24665415.
- Arendt, J. F.; Nexo, E. (2013). "Unexpected high plasma cobalamin: Proposal for a diagnostic strategy". Clinical Chemistry and Laboratory Medicine. 51 (3): 489–496. doi:10.1515/cclm-2012-0545. PMID 23241600.
- Arendt, J. F.; Pedersen, L.; Nexo, E.; Sørensen, H. T. (2013). "Elevated plasma vitamin B12 levels as a marker for cancer: A population-based cohort study". Journal of the National Cancer Institute. 105 (23): 1799–1805. doi:10.1093/jnci/djt315. PMC . PMID 24249744.
- Ermens, A. A.; Vlasveld, L. T.; Lindemans, J. (2003). "Significance of elevated cobalamin (vitamin B12) levels in blood". Clinical Biochemistry. 36 (8): 585–590. PMID 14636871.
- Rooke, Jennifer (October 30, 2013). "Do carnivores need Vitamin B12 supplements?". Baltimore Post Examiner.
- Watanabe, F. (2007). "Vitamin B12 sources and bioavailability". Experimental Biology and Medicine. Maywood. 232 (10): 1266–1274. doi:10.3181/0703-MR-67. PMID 17959839.
- Dossey, Aaron T. (February 1, 2013). "Why Insects Should Be in Your Diet". The Scientist.
- "Vitamin B12 content, all foods ordered by content in µg per 100 g". United States Department of Agriculture, Agricultural Research Service, National Nutrient Database for Standard Reference, Release 28. May 2016. Retrieved April 6, 2017.
- Moore, S. J.; Warren, M. J. (June 1, 2012). "The anaerobic biosynthesis of vitamin B12". Biochemical Society Transactions. 40 (3): 581–586. doi:10.1042/BST20120066. PMID 22616870.
- Graham, Ross M.; Deery, Evelyne; Warren, Martin J. (2009). "18: Vitamin B12: Biosynthesis of the Corrin Ring". In Warren, Martin J.; Smith, Alison G. Tetrapyrroles Birth, Life and Death. New York, NY: Springer-Verlag. p. 286. doi:10.1007/978-0-387-78518-9_18. ISBN 978-0-387-78518-9.
- Gille, D.; Schmid, A. (February 2015). "Vitamin B12 in meat and dairy products". Nutrition Reviews. 73 (2): 106–115. doi:10.1093/nutrit/nuu011. PMID 26024497.
- McDowell, Lee Russell (2008). Vitamins in Animal and Human Nutrition (2nd ed.). Hoboken: John Wiley & Sons. pp. 525, 539. ISBN 9780470376683.
- "Vitamin B12". DSM. Retrieved January 17, 2017.
- Watanabe, F. (2007). "Vitamin B12 sources and bioavailability". Experimental Biology and Medicine. Maywood. 232 (10): 1266–1274. doi:10.3181/0703-MR-67. PMID 17959839.
- Walsh, Stephen. "Vegan Society B12 factsheet". Vegan Society. Retrieved January 17, 2008.[dead link]
- Mangels, Reed. "Vitamin B12 in the Vegan Diet". Vegetarian Resource Group. Retrieved January 17, 2008.
- "Don't Vegetarians Have Trouble Getting Enough Vitamin B12?". Physicians Committee for Responsible Medicine. Retrieved January 17, 2008.
- Sharabi, A.; Cohen, E.; Sulkes, J.; Garty, M. (2003). "Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route". British Journal of Clinical Pharmacology. 56 (6): 635–638. doi:10.1046/j.1365-2125.2003.01907.x. PMC . PMID 14616423.
- Bolaman, Z.; Kadıköylü, G.; Yükselen, V.; Yavaşoğlu, I.; Barutça, S.; Şentürk, T. (2003). "Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study". Clinical Therapeutics. 25 (12): 3124–3134. doi:10.1016/S0149-2918(03)90096-8. PMID 14749150.
- Lane, L. A.; Rojas Fernández, C. (2002). "Treatment of vitamin B12-deficiency anemia: oral versus parenteral therapy". Annals of Pharmacotherapy. 36 (7–8): 1268–1272. doi:10.1345/aph.1A122. PMID 12086562.
- Butler, C. C. (2006). "Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: A systematic review of randomized controlled trials". Family Practice. 23 (3): 279–285. doi:10.1093/fampra/cml008. PMID 16585128.
- Andersson, H. C.; Shapira, E. (1998). "Biochemical and clinical response to hydroxocobalamin versus cyanocobalamin treatment in patients with methylmalonic acidemia and homocystinuria (cblC)". Journal of Pediatrics. 132 (1): 121–124. doi:10.1016/S0022-3476(98)70496-2. PMID 9470012.
- Roze, E.; Gervais, D.; Demeret, S.; Ogier de Baulny, H.; Zittoun, J.; Benoist, J.-F.; Said, G.; Pierrot-Deseilligny, C.; Bolgert, F. (2003). "Neuropsychiatric disturbances in presumed late-onset cobalamin C disease". Archives of Neurology. 60 (10): 1457–1462. doi:10.1001/archneur.60.10.1457. PMID 14568819.
- Thauvin-Robinet, C.; Roze, E.; Couvreur, G.; Horellou, M.-H.; Sedel, F.; Grabli, D.; Bruneteau, G.; Tonneti, C.; Masurel-Paulet, A.; Perennou, D.; Moreau, T.; Giroud, M.; Ogier de Baulny, H.; Giraudier, S.; Faivre, L. (2008). "The adolescent and adult form of cobalamin C disease: clinical and molecular spectrum". Journal of Neurology, Neurosurgery, and Psychiatry. 79 (6): 725–728. doi:10.1136/jnnp.2007.133025. PMID 18245139.
- Heil, S. G.; Hogeveen, M; Kluijtmans, L. A.; Van Dijken, P. J.; Van de Berg, G. B.; Blom, H. J.; Morava, E. (2007). "Marfanoid features in a child with combined methylmalonic aciduria and homocystinuria (cblC type)". Journal of Inherited Metabolic Disease. 30 (5): 811. doi:10.1007/s10545-007-0546-6. PMID 17768669.
- Tsai, A. C. H.; Morel, C. F.; Scharer, G.; Yang, M.; Lerner-Ellis, J. P.; Rosenblatt, D. S.; Thomas, J. A. (2007). "Late-onset combined homocystinuria and methylmalonic aciduria (cblC) and neuropsychiatric disturbance". American Journal of Medical Genetics Part A. 143A (20): 2430–2434. doi:10.1002/ajmg.a.31932. PMID 17853453.
- European Food Safety Authority (September 25, 2008). "5′-deoxyadenosylcobalamin and methylcobalamin as sources for Vitamin B12 added as a nutritional substance in food supplements: Scientific opinion of the Scientific Panel on Food Additives and Nutrient Sources added to food". EFSA Journal. 815 (10): 1–21. doi:10.2903/j.efsa.2008.815. "the metabolic fate and biological distribution of methylcobalamin and 5′-deoxyadenosylcobalamin are expected to be similar to that of other sources of vitamin B12 in the diet."
- Kwak, C. S.; Lee, M. S.; Lee, H. J.; Whang, J. Y.; Park, S. C. (2010). "Dietary source of vitamin B12 intake and vitamin B12 status in female elderly Koreans aged 85 and older living in rural area". Nutrition Research and Practice. 4 (3): 229–234. doi:10.4162/nrp.2010.4.3.229. PMC . PMID 20607069.
- Kwak, C. S.; Lee, M. S.; Oh, S. I.; Park, S. C. (2010). "Discovery of Novel Sources of Vitamin B12 in Traditional Korean Foods from Nutritional Surveys of Centenarians". Current Gerontology and Geriatrics Research. 2010: 1–11. doi:10.1155/2010/374897. PMC . PMID 21436999.
- Watanabe, F.; Yabuta, Y.; Bito, T.; Teng, F (2014). "Vitamin B12-Containing Plant Food Sources for Vegetarians". Nutrients. 6 (5): 1861–1873. doi:10.3390/nu6051861. PMC . PMID 24803097.
- Croft, Martin T.; Lawrence, Andrew D.; Raux-Deery, Evelyne; Warren, Martin J.; Smith, Alison G. (2005). "Algae acquire vitamin B12 through a symbiotic relationship with bacteria". Nature. 438 (7064): 90–93. doi:10.1038/nature04056. PMID 16267554.
- Albert, M. J.; Mathan, V. I.; Baker, S. J. (1980). "Vitamin B12 synthesis by human small intestinal bacteria". Nature. 283 (5749): 781–782. doi:10.1038/283781a0. PMID 7354869.
- Kelly, R. J.; Gruner, T. M.; Furlong, J. M.; Sykes, A. R. (2006). "Analysis of corrinoids in ovine tissues". Biomedical Chromatography. 20 (8): 806–814. doi:10.1002/bmc.604. PMID 16345011.
- Yamada, K.; Shimodaira, M.; Chida, S.; Yamada, N.; Matsushima, N.; Fukuda, M.; Yamada, S. (2008). "Degradation of Vitamin B12 in Dietary Supplements". International Journal for Vitamin and Nutrition Research. 78 (45): 195–203. doi:10.1024/0300-98184.108.40.206. PMID 19326342.
- Watanabe, F.; Katsura, H.; Takenaka, S.; Fujita, T.; Abe, K.; Tamura, Y.; Nakatsuka, T.; Nakano, Y. (1999). "Pseudovitamin B12 is the predominant cobamide of an algal health food, Spirulina tablets". Journal of Agricultural and Food Chemistry. 47 (11): 4736–4741. doi:10.1021/jf990541b. PMID 10552882.
- Yamada, K.; Yamada, Y.; Fukuda, M.; Yamada, S. (1999). "Bioavailability of dried asakusanori (Porphyra tenera) as a source of Cobalamin (Vitamin B12)". International Journal for Vitamin and Nutrition Research. 69 (6): 412–418. doi:10.1024/0300-98220.127.116.112. PMID 10642899.
- De Jager, J.; Kooy, A.; Lehert, P.; Wulffelé, M. G.; Van Der Kolk, J.; Bets, D.; Verburg, J.; Donker, A. J. M.; Stehouwer, C. D. A. (2010). "Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B12 deficiency: Randomised placebo controlled trial". BMJ. 340: c2181. doi:10.1136/bmj.c2181. PMC . PMID 20488910.
- Andrès, E.; Noel, E.; Goichot, B. (2002). "Metformin-associated vitamin B12 deficiency". Archives of Internal Medicine. 162 (19): 2251–2252. doi:10.1001/archinte.162.19.2251-a. PMID 12390080.
- Gilligan, M. (2002). "Metformin and vitamin B12 deficiency". Archives of Internal Medicine. 162 (4): 484–485. doi:10.1001/archinte.162.4.484. PMID 11863489.
- Bauman, W. A.; Shaw, S.; Jayatilleke, E.; Spungen, A. M.; Herbert, V. (2000). "Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin". Diabetes Care. 23 (9): 1227–1231. doi:10.2337/diacare.23.9.1227. PMID 10977010.
- Copp, Samantha (December 1, 2007). "What effect does metformin have on vitamin B12 levels?". UK Medicines Information, NHS. Archived from the original on September 27, 2007.
- Voet,, Judith G.; Voet, Donald (1995). Biochemistry. New York: J. Wiley & Sons. p. 675. ISBN 0-471-58651-X. OCLC 31819701.
- Banerjee, R.; Ragsdale, S. W. (2003). "The many faces of vitamin B12: catalysis by cobalamin-dependent enzymes". Annual Review of Biochemistry. 72: 209–247. doi:10.1146/annurev.biochem.72.121801.161828. PMID 14527323.
- Banerjee, R. V.; Matthews, R. G. (1990). "Cobalamin-dependent methionine synthase". The FASEB Journal. 4 (5): 1450–1459. PMID 2407589.
- Wickramasinghe, S. N. (1995). "Morphology, biology and biochemistry of cobalamin- and folate-deficient bone marrow cells". Baillière's Clinical Haematology. 8 (3): 441–459. doi:10.1016/S0950-3536(05)80215-X. PMID 8534956.
- Naidich, M. J.; Ho, S. U. (2005). "Case 87: Subacute combined degeneration". Radiology. 237 (1): 101–105. doi:10.1148/radiol.2371031757. PMID 16183926.
- "CerefolinNAC® Caplets" (PDF). intetlab.com.
- Marks, Allan D. (2009). Basic Medical Biochemistry: A Clinical Approach (3rd ed.). Lippincott, Williams & Wilkins. p. 757. ISBN 078177022X.
- Allen, R. H.; Seetharam, B.; Podell, E.; Alpers, D.H . (1978). "Effect of Proteolytic Enzymes on the Binding of Cobalamin to R Protein and Intrinsic Factor". Journal of Clinical Investigation. 61 (1): 47–54. doi:10.1172/JCI108924. PMC . PMID 22556.
- Combs, Gerald F. (2008). The vitamins: fundamental aspects in nutrition and health (3rd ed.). Amsterdam: Elsevier Academic Press. ISBN 0-12-183492-1. OCLC 150255807.[page needed]
- Abels, J.; Vegter, J. J. M.; Woldring, M. G.; Jans, J. H.; Nieweg, H. O. (2009). "The Physiologic Mechanism of Vitamin B12 Absorption". Acta Medica Scandinavica. 165 (2): 105–113. doi:10.1111/j.0954-6820.1959.tb14477.x.
- Kuzminski, A. M.; Del Giacco, E. J.; Allen, R. H.; Stabler, S. P.; Lindenbaum, J. (August 1998). "Effective treatment of cobalamin deficiency with oral cobalamin". Blood. 92 (4): 1191–1198. PMID 9694707.
- "If a person stops consuming the vitamin, the body's stores of this vitamin usually take about 3 to 5 years to exhaust".
- "B12: An essential part of a healthy plant-based diet". International Vegetarian Union.
- Jaouen, G., ed. (2006). Bioorganometallics: Biomolecules, Labeling, Medicine. Weinheim: Wiley-VCH. ISBN 3-527-30990-X.[page needed]
- Loeffler, G. (2005). Basiswissen Biochemie. Heidelberg: Springer. p. 606. ISBN 3-540-23885-9.
- Bertrand, E. M.; Saito, M. A.; Young, J. J.; Neilan, B. A. (2011). "Vitamin B12 biosynthesis gene diversity in the Ross Sea: the identification of a new group of putative polar B12 biosynthesizers". Environmental Microbiology. 13 (5): 1285–1298. doi:10.1111/j.1462-2920.2011.02428.x. PMID 21410623.
- Khan, Adil Ghani; Eswaran, S. V. (2003). "Woodward's synthesis of vitamin B12". Resonance. 8 (6): 8–16. doi:10.1007/BF02837864.
- Eschenmoser, A.; Wintner, C. E. (June 1977). "Natural product synthesis and vitamin B12". Science. 196 (4297): 1410–1420. doi:10.1126/science.867037. PMID 867037.
- Riether, Doris; Mulzer, Johann (2003). "Total Synthesis of Cobyric Acid: Historical Development and Recent Synthetic Innovations". European Journal of Organic Chemistry. 2003: 30–45. doi:10.1002/1099-0690(200301)2003:1<30::AID-EJOC30>3.0.CO;2-I.
- Martens, J. H.; Barg, H.; Warren, M. J.; Jahn, D. (2002). "Microbial production of vitamin B12". Applied Microbiology and Biotechnology. 58 (3): 275–285. doi:10.1007/s00253-001-0902-7. PMID 11935176.
- Linnell, J. C.; Matthews, D. M. (1984). "Cobalamin metabolism and its clinical aspects". Clinical Science. 66 (2): 113–121. PMID 6420106.
- 21 C.F.R. 184.1945
- De Baets, S.; Vandedrinck, S.; Vandamme, E. J. (2000). "Vitamins and Related Biofactors, Microbial Production". In Lederberg, J. Encyclopedia of Microbiology. 4 (2nd ed.). New York: Academic Press. pp. 837–853. ISBN 0-12-226800-8.
- Riaz, Muhammad; Iqbal, Fouzia; Akram, Muhammad (2007). "Microbial production of vitamin B12 by methanol utilizing strain of Pseudomonas species". Pakistan Journal of Biochemistry & Molecular Biology. 1. 40: 5–10.
- Zhang, Yemei (January 26, 2009). "New round of price slashing in vitamin B12 sector (Fine and Specialty)". China Chemical Reporter.
- "Mary Shorb Lecture in Nutrition". Retrieved March 3, 2016.
- Shorb, Mary Shaw (May 10, 2012). "Annual Lecture". Department of Animal & Avian Sciences, University of Maryland.
- Kirkland, Kyle (2010). Biological Sciences: Notable Research and Discoveries. Facts on File. p. 87. ISBN 0816074399.